Investing in Cell and Gene Technology

November 1, 2019

A number of experts will be examining investment opportunities within the evolving cell and gene therapy sector, in a panel discussion on Wednesday morning (Nov. 6, 2019) during CPhI Worldwide in Frankfurt, Germany.

A number of experts will be examining investment opportunities within the evolving cell and gene therapy sector, in a panel discussion on Wednesday morning (Nov. 6, 2019) during CPhI Worldwide in Frankfurt, Germany.

As cell and gene therapies are garnering more interest within the industry and finding use for the treatment of patients who had previously unmet needs, regulators have started to prepare for increased products in the sector. As a result of the sector’s potential, it is inevitable that there will be a certain degree of commercial opportunities available for companies.

In the panel discussion, experts will specifically look at the sector outlook, long-term opportunities, potential challenges in commercialization and pricing, the right investments for contract development and manufacturing organizations, and dynamics of logistics and supply. The panel will include, Fatma Aybegum Senkesen (Lonza), Fiona Barry (PharmSource-a GlobalData Product), Dr. Malte Kremer (Strategy&), Andy Lewin (Oxford BioMedica), Paolo Morgese (ALira Health), Chris Murphy (Thermo Fisher Scientific), Angela Tsang Myers (MilliporeSigma), and Dr. Thomas VanCott (Paragon Bioservices).

Understanding the Cell & Gene Technology Opportunity

Wednesday Nov. 6, 2019

10:30–11:40

ICSE Theatre (120D40)